GPGrossPatternRESEARCH SYSTEM
SEC CHECK OPERATIONAL
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

ULTA · Oct 29, 2016

Ulta Beauty, Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration

State dimensions

Filing0001193125-16-782523General Corporate
Capex intensity90thOwn-history percentile · N=20
Evidence method

Level · gp.fundamentals.capex_revenue_ratio

11.63% · OPTIONAL · VALID

Revenue growth89thOwn-history percentile · N=18
Evidence method

Yoy · gp.fundamentals.revenue

24.22% · CORE · VALID

Gross margin95thOwn-history percentile · N=20
Evidence method

Level · gp.fundamentals.gross_margin

37.75% · CORE · VALID

Operating margin55thOwn-history percentile · N=20
Evidence method

Level · gp.fundamentals.operating_margin

12.35% · CORE · VALID

SBC intensity30thOwn-history percentile · N=20
Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

0.47% · OPTIONAL · VALID

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History62 statesSelf-history eligible
Period transition

What moved in the state?

Capex Intensity Increased
Previous
8.91%
Current
11.63%
Delta
2.72%
Growth Increased
Previous
21.92%
Current
24.22%
Delta
2.30%
Margin Increased
Previous
35.99%
Current
37.75%
Delta
1.76%
Profitability Decreased
Previous
13.45%
Current
12.35%
Delta
-1.10%
Sbc Intensity Increased
Previous
0.45%
Current
0.47%
Delta
0.02%
Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.
Research Graph

Related governed research

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.